Sept. 11 Company Quick Takes: Glaxo to buy Sitari; plus Aimmune, Xeris, Puma and United Therapeutics
GSK acquires celiac company Sitari
GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) is acquiring Sitari Pharmaceuticals Inc. (La Jolla, Calif.), the first company formed and funded under a 2013 build-to-buy partnership between Avalon Ventures and the pharma. Financial terms are undisclosed. Sitari has conducted preclinical testing of transglutaminase 2 (TGM2; TG2) inhibitors to treat celiac disease.
Aimmune gains on peanut allergy adcomm documents
Aimmune Therapeutics Inc. (NASDAQ: AIMT) rose $3.40 (15%) to $25.46 on Wednesday after FDA released briefing documents ahead of a Friday meeting to discuss the company’s peanut allergy candidate that appeared to lack any unexpected concerns. The Allergenic Products Advisory Committee meeting will focus on whether safety and efficacy data for Palforzia (AR101) support approval to reduce incidence and severity of allergic reactions to peanuts after accidental exposure in patients aged 4-17...